Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019

Date : 04/30/2019 @ 9:30PM
Source : PR Newswire (US)
Stock : Synthetic Biologics Inc (SYN)
Quote : 0.537  -0.0027 (-0.50%) @ 10:59PM

Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019

Synthetic Biologics (AMEX:SYN)
Historical Stock Chart

6 Months : From Mar 2019 to Sep 2019

Click Here for more Synthetic Biologics Charts.

ROCKVILLE, Md., April 30, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights and financial results for the quarter ended March 31, 2019 on Wednesday, May 8, 2019, and to host a conference call the same day at 4:30 p.m. ET. The dial-in information for the call is as follows:

Synthetic Biologics, Inc.  www.syntheticbiologics.com (PRNewsFoto/Synthetic Biologics, Inc.)

U.S. (toll free): 1-888-347-5280 
International: +1 412-902-4280

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/30393. An archived replay of the call will be available for approximately ninety (90) days at the same URL, https://www.webcaster4.com/Webcast/Page/1096/30393 beginning approximately one hour after the call's conclusion.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE American: SYN) is a clinical-stage company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, C. difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company's preclinical pursuits include SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases as well as monoclonal antibody therapies for the prevention and treatment of pertussis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.     

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-2019-first-quarter-operational-highlights-and-financial-results-on-may-8-2019-300841094.html

SOURCE Synthetic Biologics, Inc.

Copyright 2019 PR Newswire

Latest SYN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.